What Пимафукорт treats: Main Uses and Benefits

The core therapeutic function of this combination medication is to address skin conditions where inflammation and infection coexist. This anti-inflammatory and anti-infective approach is utilized in clinical settings involving acute or unstable symptom patterns.

This medicine is commonly used for managing corticosteroid-responsive skin conditions such as eczema, dermatitis, and intertrigo, particularly when they are complicated by the presence of both susceptible bacteria and Candida-type fungal elements. This supports the management of complex, mixed-aetiology skin disorders by providing comprehensive symptomatic assistance.

The drug helps address symptom clusters that may become intense or disruptive, specifically focusing on pronounced inflammatory signs, including redness, swelling, and acute irritation. Its anti-inflammatory component is commonly used to help with easing the intensely distressing symptom of itching (pruritus) associated with these lesions. This approach supports comfort during symptomatic periods.

Quick Fact: Relief for Inflammatory Symptoms

Property	Description
Primary Target	Corticosteroid-responsive dermatoses with secondary microbial contamination
Symptom Focus	Redness, swelling, acute irritation, and persistent itching (pruritus)
General Benefit	Supports comfort and eases the overall symptom burden during acute episodes
Use Context	Applied in clinical settings that involve acute or unstable symptom patterns

Regulatory References

1. New Zealand Medsafe Guidance

This section outlines the officially documented population eligibility and non-eligibility for Пимафукорт (Pimafucort) as defined in regulatory labeling.

Contraindications and Eligibility Restrictions

Eligibility Scope	Official Regulatory Statement
Populations for whom use is allowed	Patients with corticosteroid-responsive skin conditions complicated by secondary bacterial or Candida infections.
Absolute Contraindications	Known hypersensitivity to Natamycin, Neomycin, Hydrocortisone, or any excipient. Use is prohibited in primary viral (e.g., Herpes), fungal, bacterial, or parasitic skin infections.
	Contraindicated for use on wounds, ulcerous skin disorders, burns, or areas with existing corticosteroid damage (striae atrophicae).
Pregnancy Eligibility Status	Restricted Use. Should not be applied on large skin surfaces, for long periods, or under occlusion due to the theoretical risk of foetal ototoxicity from Neomycin.
Pediatric Use	Use in children/infants requires caution regarding application to extensive areas or under occlusion due to the risk of systemic effects (inhibition of adrenocortical function).
Site Restrictions	Contraindicated in the external ear canal if the eardrum is perforated. Application to the eyelids is restricted due to ophthalmic risk.

Eligibility is strictly defined by regulatory documents, which permit use only when inflammation is complicated by specific secondary infections, while imposing absolute exclusions for primary pathogens, specific existing skin comorbidities, and known component allergies.

Interactions with other medicines and products

The officially documented interaction profile for this topical medicine is defined by the potential for systemic absorption of its active ingredients, Hydrocortisone and Neomycin. The resulting interactions are primarily categorized as pharmacokinetic and pharmacodynamic, based on official regulatory documentation.

Pharmacokinetic Interactions: Systemic Exposure Modification

The metabolism of the Hydrocortisone component may be affected by co-administration with strong inhibitors of the CYP3A4 enzyme, such as certain systemic antifungals (e.g., Itraconazole) or antivirals (e.g., Ritonavir). This interaction is documented to reduce the metabolic clearance of the corticosteroid, which may increase its systemic plasma exposure. This risk is contingent upon significant absorption from the application site, as detailed in regulatory texts.

Pharmacodynamic Interactions: Additive Toxicity

When the Neomycin component is absorbed into the bloodstream, a risk of additive organ toxicity exists. Regulatory documentation notes that concurrent use with other agents known to cause nephrotoxicity (kidney damage) or ototoxicity (inner ear damage), such as certain loop diuretics or other aminoglycosides, may enhance these organ-specific adverse effects.

Interaction Risk Escalation

The overall clinical relevance of these systemic interactions is directly tied to the extent of drug absorption. Regulatory authorities state that systemic uptake is significantly increased when the product is applied to non-intact or broken skin, used over a large body surface area, or applied under an occlusive dressing. These documented conditions escalate the potential for both pharmacokinetic and pharmacodynamic interactions.

Пимафукорт is a combination agent with three distinct mechanistic components: hydrocortisone, natamycin, and neomycin.

Hydrocortisone is a glucocorticoid receptor (GR) agonist. Upon topical administration, it permeates cellular membranes and binds to cytosolic GR, forming a ligand-receptor complex. This complex translocates to the nucleus where it modulates gene transcription. Specifically, it induces the synthesis of anti-inflammatory proteins, such as annexin A1 (lipocortin), and represses the transcription of pro-inflammatory mediators, including cyclooxygenase-2 (COX-2), various cytokines, and chemokines. The resulting intracellular cascade suppresses local cellular activation and reduces the systemic release of inflammatory factors.

Natamycin is a polyene macrolide antifungal agent. Its fungicidal mechanism involves high-affinity binding to ergosterol, a crucial sterol component of the fungal plasma membrane. This interaction disrupts membrane integrity and function, preventing essential ergosterol-dependent processes like vesicle fusion and fission, leading to the inhibition of fungal growth and proliferation.

Neomycin is an aminoglycoside antibiotic. It acts as an inhibitor of bacterial protein synthesis. Neomycin is selectively transported into the bacterial cell where it binds irreversibly to the 30S ribosomal subunit. This binding disrupts the initiation complex formation and causes misreading of the mRNA template, leading to the incorporation of incorrect amino acids into the nascent polypeptide chain. This translational infidelity results in the production of non-functional, truncated proteins, culminating in a bactericidal effect.

Administration Scope

Feature	Official Instruction
Route of administration	Topical application only (applied directly to the skin).
Dosing schedule (quantity)	Apply a thin layer to the affected skin area sparingly.
Frequency and timing	Application is typically performed 2 to 4 times daily (BID to QID). Use the medicine at approximately the same time each day for consistency.
Form selection	The cream form is often used for moist or acute lesions, while the ointment is recommended for dry or chronic, scaly skin conditions.

---

Use Pattern and Duration Rules

Classification	Regulatory Instruction
Administration method type	Topical (Dermatological)
Frequency pattern	Multiple times per day (up to 4)
Course duration limit	Treatment must be for short-term use only, not exceeding 14 days.
Pediatric use rule	Maximum duration of use is often shorter in infants and children to reduce the risk of absorption.
Missed-dose rule	Apply the missed dose as soon as it is remembered. If it is nearly time for the next application, skip the missed dose and maintain the regular schedule; do not apply a double amount.

---

Resulting Procedural Structure

Official step sequence:

• Select the appropriate form (cream or ointment) based on the dryness or moisture of the skin lesion.
• Apply a thin, sparing layer of the preparation to the affected area.
• Repeat this application 2 to 4 times a day.
• Treatment must be stopped if the condition shows no improvement within 7 days.
• The total course of treatment must not be continued for longer than 14 days.

This instruction map defines a precise, localized, and time-restricted protocol for using the medicine, requiring adherence to the specified quantity and frequency. The standardized protocol limits the duration to a short-term course, establishing the boundaries for its use.

Research Evidence / Overview of Studies for Пимафукорт (Pimafucort)

---

Evidence for Use in Corticosteroid-Responsive Dermatoses with Mixed Infection

The research surrounding Пимафукорт has been relevant in trials assessing short-term, episodic symptom patterns in skin conditions like eczema or dermatitis that are complicated by secondary infection. This combination was evaluated in studies that examined patient populations where inflammation, bacteria, and Candida yeast were present. Researchers primarily used short-term randomized controlled trials (RCTs) and supporting clinical experience reports to examine outcomes related to physical discomfort. Studies monitored how symptoms evolved in the observed populations, with outcomes including measurements of changes in acute signs of inflammation, such as redness and swelling, and patient-reported outcomes describing perceived discomfort, like itching (pruritus).

Studies reported how symptoms evolved in the observed populations during the short treatment period, typically 7 to 14 days, which was observed in studies exploring combination topical approaches. Findings describe patterns observed in the studies related to acute or disruptive episodes where symptoms become more noticeable. Research describes the evaluation of this combination in clinical contexts involving fluctuating or unstable symptoms, where the three active agents were studied together in studies examining mixed-aetiology skin disorders.

Evidence for Use in Intertrigo with Secondary Contamination

Research examined the combination medicine in the context of intertrigo, which are conditions in skin folds associated with acute or disruptive episodes, often complicated by moisture and microbial growth. The evidence base includes historical clinical experience reports and observational settings evaluating this formulation for conditions characterized by inflammation alongside bacterial and Candida contamination. Studies explored how the combination was associated with changes measured during the study period, focusing on outcomes linked to inflammatory or irritative states in these specific areas of the skin, such as measured changes in redness and weeping.

Research highlights changes measured during the short study period, with findings are part of the published scientific literature for combination topical therapies. Findings describe patterns observed in the studies related to symptom changes observed in the skin fold populations. However, evidence quality varies across studies, with a noted reliance on historical data and clinical observation rather than a large body of recent, specific placebo-controlled RCTs.

Key Studies & References

1. PIMAFUCORT® NEW ZEALAND DATA SHEET - Product information on Hydrocortisone, Natamycin, and Neomycin
2. Topical antiseptic cream instead of a topical antibiotic for minor skin infections? - Best Practice Journal (BPJ 68) Review

Common questions about Пимафукорт (FAQ)

Q: How does the action of Пимафукорт differ from a simple antifungal cream?

A: Пимафукорт is a fixed-dose combination product, meaning it contains three distinct active ingredients: an antifungal, an antibiotic, and an anti-inflammatory steroid. Official documentation indicates this medicine is intended for conditions where this triple therapeutic approach is appropriate for specific clinical situations. A simple antifungal cream contains only one active ingredient.

Q: Is it allowed to apply Пимафукорт to the face or other sensitive areas?

A: Regulatory documents state that the skin on the face, hairy areas, and genitals are particularly sensitive to the local effects of this medicine. For this reason, application to these areas is subject to special considerations due to increased sensitivity. The product label also lists specific restrictions for use on the eyelids or in the external ear canal if the eardrum is perforated.

Q: Can the medication be used on the scalp or on hair-covered areas?

A: Regulatory documentation notes that hairy skin areas are particularly sensitive to the local effects of the medicine. Due to this increased sensitivity, application to such areas is associated with increased sensitivity.

Q: Is Пимафукорт considered a high-strength, moderate-strength, or low-strength topical steroid?

A: The corticosteroid component of the medicine is Hydrocortisone. Regulatory warnings describe this component as having a specific profile of potential side effects relative to stronger corticosteroid options.

Q: Why is it noted that the drug should not be used for more than 4 weeks?

A: Official regulatory instructions specify that the treatment course for this medicine must be for short-term use only, with a maximum duration typically not exceeding 14 days. This short-term limit is established due to the potential for developing steroid-related side effects.

Q: Are there risks of the skin becoming dependent on Пимафукорт with prolonged use?

A: Regulatory documentation notes a potential side effect known as the “rebound effect,” which is associated with the long-term use of topical corticosteroids. This rebound effect is described as the original skin problem worsening upon discontinuation, which regulatory documents associate with the rebound effect.

Q: Why might a patient experience a flare-up of symptoms shortly after stopping the use of Пимафукорт?

A: The regulatory data sheet lists the 'rebound effect' as a potential side effect that may occur when the medicine is stopped. This rebound effect is described as a potential worsening of the original skin condition shortly after discontinuation.

Q: What are the signs of a potential allergic reaction to the neomycin (antibiotic) component?

A: Signs of a potential allergic reaction, as listed in the patient leaflet, include observable symptoms such as shortness of breath, wheezing, or difficulty breathing. Other signs may involve swelling of the face, lips, or tongue, or the development of rash, itching, or hives on the skin.

Q: Is there a known risk of developing resistance to the antibiotic component (neomycin)?

A: Regulatory warnings note that cross-resistance between the neomycin component and other antibiotics belonging to the aminoglycoside group may occur. This is a general risk associated with the use of topical antibiotics.

Q: Can Пимафукорт cause changes in skin color (hyperpigmentation or hypopigmentation)?

A: According to official regulatory documents, discoloration or depigmentation of the skin is listed as a potential local side effect. This effect is associated with the corticosteroid component of the medicine.

Q: Does the natamycin component of Пимафукорт treat all types of fungal infections?

A: Official regulatory texts describe the Natamycin component as having a spectrum of action against yeasts, such as Candida, and filamentous fungi. The product is intended for conditions where the triple action of its components is appropriate.

Q: Does the vehicle (cream base vs. ointment base) impact the side effect profile of Пимафукорт?

A: General regulatory and prescribing data note that the occlusive nature of an ointment base may potentially enhance the absorption and local potency of the corticosteroid. This differs from a cream base, which is generally less occlusive.

Q: Is it important to wash hands immediately after applying Пимафукорт?

A: Washing hands immediately after application is a safety practice commonly cited in public health guidelines for topical medicines. This practice helps to prevent unnecessary spread and limit unintended absorption.

Q: What happens if a small amount of Пимафукорт is accidentally swallowed?

A: The patient information leaflet and overdose guidelines direct the user to seek immediate medical attention in the event of accidental ingestion. This is to allow a healthcare professional to assess the situation and determine the appropriate course of action.

Q: What action is generally recommended if symptoms do not improve after the expected duration of use?

A: Official patient information states that if the skin condition does not show a positive response to treatment within the first 7 days, it stipulates consulting a healthcare professional. This guideline is in place to ensure that the proper diagnosis is confirmed.

Storage and Disposal Requirements

Official regulatory guidelines establish specific requirements for storing and discarding Пимафукорт cream and ointment.

Storage Conditions

The medicine must be stored strictly below 25 C in a cool, dry place and should not be frozen. It must be kept in the original container and the tube should be kept tightly closed after each use to maintain product stability. If an in-use shelf life is specified, the product must be discarded one month after first opening.

Disposal and Safety

For safety, the product must be stored out of the sight and reach of children. Unused or expired medicine should be returned to a pharmacist or designated drug take-back program for proper disposal. The product should not be disposed of via wastewater or routine household waste.